Filtered By:
Condition: Pulmonary Hypertension
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Neuroprotective effects of dynamic bubble trap use in patients undergoing pulmonary endarterectomy: a two-arm randomized controlled trial
CONCLUSIONS: DBT positively influences memory function after PEA. This effect is most likely caused by the reduction of gaseous microemboli.TRIAL REGISTRATION: This study is registered in the German Clinical Trials Register, ID: DRKS00021499.PMID:34795929 | PMC:PMC8575830 | DOI:10.21037/jtd-21-831
Source: Journal of Thoracic Disease - November 19, 2021 Category: Respiratory Medicine Authors: Jasmin El Shazly Tibo Gerriets Juergen Hennig Marius Butz Sabrina Kastaun Christoph B Wiedenroth Markus Schoenburg Marc Wollenschlaeger Georg Bachmann Stefan Guth Martin Juenemann Source Type: research
Cutaneous iontophoresis of vasoactive medications in patients with scleroderma ‐associated pulmonary arterial hypertension
ConclusionsPatients with SSc-PAH have a lower cutaneous microvascular response to a prostacyclin analog treprostinil and the sGC activator A-350619 when compared with patients with SSc and no evidence of PH on screening tests, presumably due to a peripheral reduction in prostacyclin receptor expression and nitric oxide bioavailability.
Source: Microcirculation - November 17, 2021 Category: Research Authors: Sami Al Abdi,
Allaa Almoushref,
Tawfeq Naal,
Celia A. Melillo,
Kulwant S. Aulak,
Mostafa K. Ahmed,
Soumya Chatterjee,
Kristin B. Highland,
Raed A. Dweik,
Adriano R. Tonelli Tags: ORIGINAL ARTICLE Source Type: research
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cutaneous Iontophoresis of Vasoactive Medications in Patients with Scleroderma ‐ Associated Pulmonary Arterial Hypertension
ConclusionsPatients with SSc-PAH have a lower cutaneous microvascular response to a prostacyclin analog treprostinil and the sGC activator A-350619 when compared with patients with SSc and no evidence of PH on screening tests, presumably due to a peripheral reduction in prostacyclin receptor expression and nitric oxide bioavailability.
Source: Microcirculation - November 6, 2021 Category: Research Authors: Sami Al Abdi,
Allaa Almoushref,
Tawfeq Naal,
Celia Melillo,
Kulwant S. Aulak,
Mostafa K. Ahmed,
Soumya Chatterjee,
Kristin Highland,
Raed A. Dweik,
Adriano R. Tonelli Tags: ORIGINAL ARTICLE Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
